Prof. Dan Roden

Professor Roden received his medical degree and training in Internal Medicine from McGill University in Montreal and then trained at Vanderbilt in Clinical Pharmacology and Cardiology. His career-long focus has been studies of the clinical, genetic, cellular and molecular basis of arrhythmia susceptibility and variability responses to arrhythmia therapies, and he is widely recognized for his expertise in drug-induced arrhythmias.

Over the last 10 years, he has also led Vanderbilt’s broader efforts in pharmacogenomics discovery and implementation.
Professor Roden is principal investigator for the Vanderbilt sites of the National Institutes of Health’s Pharmacogenomics Research Network (where he currently serves as chair of the steering committee) and the National Human Genome Research Institute’s Electronic Medical Records and Genomics Network. He directs BioVU, the Vanderbilt DNA databank that currently links DNA samples from more than 135,000 patients to de-identify electronic medical records.

Professor Roden has received the Leon Goldberg Young Investigator Award and the Rawls Palmer Progress in Science Award from the American Society for Clinical Pharmacology and Therapeutics and the Distinguished Scientist Award from both the Heart Rhythm Society and the American Heart Association.